scholarly journals Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial

2018 ◽  
Vol 21 (2) ◽  
pp. 234-243 ◽  
Author(s):  
Weiqing Wang ◽  
Luis Nevárez ◽  
Ekaterina Filippova ◽  
Ki Ho Song ◽  
Bei Tao ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Glargine ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Open Label ◽  
Phase Iii Trial ◽  
Asian Patients

scholarly journals Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety

2021 ◽  
pp. 246-255
Author(s):  
E. V. Biryukova ◽  
M. V. Shinkin ◽  
O. M. Mikheeva
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Glargine ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Acting Insulin ◽  
Modern Analogue ◽  
Long Acting

In time, prescription of insulin therapy (IT) becomes inevitable for many patients with type 2 diabetes mellitus (DM) to achieve and maintain the target hypoglycemic range.According to the current guidelines, the addition of basal insulin to glucose-lowering therapy in patients with insufficient control of type 2 diabetes, gradual titration of its dose in accordance with a fasting blood glucose level is an effective and safe method for initiating IT. The properties of modern long-acting insulin analogues are considered. Glargine 300 U/ml is a modern analogue of long-acting insulin that is intended to be used once a day. The glargine molecule forms the basis of the drug. Increasing the concentration of glargine per volume unit and formation of a smaller subcutaneous depot led to a change in the pharmacokinetic properties of the drug. Glargine 300 IU/ml provides a more stable, long-term, predictable action with low glycemic variability as compared with glargine 100 IU/ml, which reduces the risk of hypoglycemia. The sugar-reducing efficacy and safety of insulin glargine 300 U/ml as evidenced by the findings of the international clinical phase III EDITION studies are discussed. Insulin glargine 300 U/ml showed a similar decrease in HbA1c levels compared to insulin glargine 100 U/ml with an improved safety profile (lower risk of developing episodes of confirmed or severe hypoglycemia at all times of the day, including the nighttime) and a less pronounced effect on the body weight of patients with type 2 diabetes. The efficacy and safety of the use of glargine 300 U/ml has been confirmed in type 2 diabetes patients with chronic kidney disease and the elderly. In the BRIGHT study, glargine 300 U/ml showed comparable glycemic control when it is being compared. 

scholarly journals Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study

2014 ◽  
Vol 36 (1) ◽  
pp. 84-100.e9 ◽  
Author(s):  
Linong Ji ◽  
Jianhua Ma ◽  
Hongmei Li ◽  
Traci A. Mansfield ◽  
Caroline L. T’joen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Phase Iii ◽  
Asian Patients ◽  
Prospective Phase ◽  
Phase Iii Study ◽  
Drug Naïve
Sign in / Sign up

Export Citation Format

Share Document